Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 11/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 8/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.39 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.39 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2201786 | 0.87 | GRIK1 (0.47) | GRIK1GRIK2SLC7A5TDP1GRIA2 | |
| SCHEMBL2201794 | 0.87 | GRIK1 (0.47) | GRIK1GRIK2SLC7A5TDP1GRIA2 | |
| Hydrochloric Acid SCHEMBL29425835 | 0.85 | GRIK1 (0.46) | GRIK1GRIK2SLC7A5TDP1GRIA2 | |
| SCHEMBL7247897 | 0.80 | GRIK1 (0.43) | GRIK1GRIK2SLC7A5SLC1A3SLC1A2 | |
| SCHEMBL3264927 | 0.78 | TDP1 (0.50) | TDP1TSHR | |
| SCHEMBL8662604 | 0.78 | TDP1 (0.44) | GRIK1GRIK2SLC7A5TDP1SLC1A3 | |
| SCHEMBL7359265 | 0.76 | SLC1A1 (0.54) | GRIK1GRIK2SLC7A5SLC1A3SLC1A2 | |
| SCHEMBL9449386 | 0.76 | SLC1A1 (0.54) | GRIK1GRIK2SLC7A5SLC1A3SLC1A2 | |
| SCHEMBL16574651 | 0.76 | TDP1 (0.49) | TDP1TSHR | |
| SCHEMBL27458508 | 0.76 | TSHR (0.49) | TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2937334-B1 | PROPIONIC ACIDS, PROPIONIC ACID ESTERS, AND RELATED COMPOUNDS | PROMENTIS PHARM INC (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-2937334-A1 | PROPIONIC ACIDS, PROPIONIC ACID ESTERS, AND RELATED COMPOUNDS | Promentis Pharmaceuticals, Inc. (US) | 2015-10-28 | — | — | EP | disclosed |
| US-8815905-B2 | Propionic acids, propionic acid esters, and related compounds | PROMENTIS PHARMACEUTICALS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| EP-2545033-A2 | PROPIONIC ACIDS, PROPIONIC ACID ESTERS, AND RELATED COMPOUNDS | Promentis Pharmaceuticals, Inc. (US) | 2013-01-16 | — | — | EP | disclosed |
| WO-2011112535-A2 | PROPIONIC ACIDS, PROPIONIC ACID ESTERS, AND RELATED COMPOUNDS | PROMENTIS PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| US-20110224156-A1 | Propionic Acids, Propionic Acid Esters, and Related Compounds | ALBANY MOLECULAR RESEARCH, INC. | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224156-A1 | Propionic Acids, Propionic Acid Esters, and Related Compounds | PCCA, PC, PMP22 | GRIK1 27/4885GRIK2 26/4885SLC7A5 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.